Sartorius stock heads toward October 22 results with targets split

Published on 10/07/2026 at 14:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius stock approaches its October 22 results date as consensus targets EUR 271.21 from 20 analysts. RBC keeps a EUR 220 target and Sector Perform rating.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern — Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius AG (ISIN DE0007165631) was last at EUR 259.20 on Xetra on October 7, 2026 at 1:56 p.m. CEST, down 0.19 percent from the previous close. The preference share is 4.67 percent below its 52-week high of EUR 271.90, putting the October 22 results date at the center of the investment case.

October 22 sets the next test

According to finanzen.ch on October 7, 2026, Sartorius is scheduled to publish figures for the quarter ended September 30, 2026, on October 22, 2026. The same estimate points to quarterly revenue of EUR 895.9 million, up 6.25 percent from EUR 843.2 million in the prior-year quarter, while seven analysts expect earnings per share of EUR 1.25 versus EUR 0.630.

The comparison matters because the prior quarter showed a different earnings profile. Standardized financial data put second-quarter revenue at EUR 911.8 million and net income at EUR 65.9 million, after first-quarter revenue of EUR 899.1 million and net income of EUR 56.2 million. The upcoming release will show whether the expected revenue increase is accompanied by further earnings improvement.

Analysts disagree on valuation

RBC kept Sartorius at Sector Perform with a EUR 220 price target in a statement published on October 6, 2026, according to FinanzNachrichten. RBC adjusted its model for tariff refunds, the Mattek acquisition and currency movements, while describing the 2026 revenue effect as minimal.

Goldman Sachs raised its target from EUR 228 to EUR 244 and kept a Neutral rating on October 1, 2026, as FinanzNachrichten reported. The bank said Bioprocessing recovery was progressing and placed its third-quarter operating profit forecast slightly above consensus.

The broader consensus is more constructive. MarketScreener lists an Outperform consensus from 20 analysts, an average target of EUR 271.21, a high target of EUR 307.00 and a low target of EUR 190.00. The average target lies 4.64 percent above the October 7 price, leaving the results as the next concrete test of that valuation.

Stock remains below yearly high

Sartorius stock traded between EUR 256.60 and EUR 261.30 on October 7, 2026, with 21,875 shares changing hands at the recorded time. Its 52-week range is EUR 198.50 to EUR 271.90, while market capitalization stands at EUR 17.9 billion as of October 7, 2026.